- /
- Supported exchanges
- / US
- / NDOI.OTCQX
Endo, Inc. (NDOI OTCQX) stock market data APIs
Endo, Inc. Financial Data Overview
Endo, Inc. operates as a specialty pharmaceutical company that develops, manufactures, markets, and sells various pharmaceutical products and provides life-enhancing therapies in the United States and internationally. It offers specialty medicines, sterile injectables, and generic products. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It also develops additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty. The company offers ADRENALIN, a non-selective alpha and beta adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and APLISOL, a sterile aqueous solution of a purified protein derivative for intradermal administration for aid in the diagnosis of tuberculosis. In addition, it offers SUPPRELIN LA, a soft flexible 12-month hydrogel implant based on hydrogel polymer technology that delivers histrelin acetate, a gonadotropin-releasing hormone agonist, and is indicated for the treatment of CPP in children; AVEED, a long-acting testosterone undecanoate for injection for the treatment of hypogonadism; TESTOPEL, a unique, long-acting implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX, a penile injection used to treat erectile dysfunction caused by conditions affecting nerves, blood vessels, emotions and/or a combination of factors. It provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. The company was founded in 1997 and is based in Malvern, Pennsylvania with additional offices in Dublin, Ireland; and Woodcliff Lake, New
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Endo, Inc. data using free add-ons & libraries
Get Endo, Inc. Fundamental Data
Endo, Inc. Fundamental data includes:
- Net Revenue: 1 733 M
- EBITDA: -79 375 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: 0.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Endo, Inc. News
New
[Latest] Global Aspirin Market Size/Share Worth USD 3.40 Billion by 2034 at a 3.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Aspirin Market size & share revenue was value...
Mallinckrodt Names Leslie Donato to Board of Directors
Appointment of Former Cencora Executive Completes Nine-Member Board DUBLIN, Aug. 4, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that Leslie Donato has been appointed to the Company's Board...
S&P Global raises Endo ratings on Mallinckrodt merger completion
Investing.com -- S&P Global Ratings has raised its rating on Endo Inc. to ’BB-’ from ’B+’ and assigned a stable outlook following the completion of its merger with Mallinckrodt (OTC:MNKKQ) P...
Mallinckrodt And Endo Shareholders Approve Merger
(RTTNews) - Mallinckrodt plc and Endo, Inc. (NDOI) have secured the necessary shareholder approvals to proceed with their merger, a stock-and-cash transaction aimed at forming a global, diversified ph...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.